Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
FEMS Yeast Res ; 22(1)2022 01 27.
Artículo en Inglés | MEDLINE | ID: mdl-35040997

RESUMEN

The increasing prevalence of fluconazole-resistant clinical isolates of Candida spp. strongly hinders the widespread use of the drug. To tackle this problem, great efforts have been made to fully understand the fungal response to fluconazole. In this work, we show that the role of Zap1 in Candida glabrata goes beyond regulating yeast adaptation to zinc deficiency. In line with our previous observation that deletion of ZAP1 makes yeast cells more sensitive to fluconazole, we found that the mutant CgΔzap1 accumulates higher levels of the drug, which correlates well with its lower levels of ergosterol. Surprisingly, Zap1 is a negative regulator of the drug efflux transporter gene CDR1 and of its regulator, PDR1. The apparent paradox of drug accumulation in cells where genes encoding transporters relevant for drug extrusion are being overexpressed led us to postulate that their activity could be impaired. In agreement, Zap1-depleted cells present, in addition to decreased ergosterol levels, an altered composition of membrane phospholipids, which together should impact membrane function and impair the detoxification of fluconazole. Overall, our study brings to light Zap1 as an important hub in Candida glabrata response to fluconazole.


Asunto(s)
Candida glabrata , Fluconazol , Proteínas Fúngicas , Antifúngicos/farmacología , Candida , Candida glabrata/efectos de los fármacos , Candida glabrata/genética , Farmacorresistencia Fúngica , Ergosterol , Fluconazol/farmacología , Proteínas Fúngicas/genética , Proteínas Fúngicas/farmacología , Pruebas de Sensibilidad Microbiana
3.
J Biol Inorg Chem ; 25(8): 1117-1128, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33104887

RESUMEN

Invasive fungal infections (IFIs) are life threatening and existing antifungal drugs are not completely effective due to undesirable side effects and resistance emergence. Azoles are often the treatment of choice for IFIs and growing evidence suggests that copper can act synergistically with these drugs. In this work, we designed a compound bringing together azole and copper(II)-binding groups and studied the molecular mechanisms underlying its biological toxicity. Our results show that both the compound, 4, and its copper(II) complex, Cu.4, are active against Candida spp. We found that Cu.4 acts as a copper(II) ionophore, which results in the intracellular accumulation of reactive oxygen species (ROS), whereas compound 4 is an iron chelator and exerts its toxicity by decreasing iron bioavailability. Interestingly, while 4 is not very toxic to macrophages or HeLa cells, Cu.4 significantly affects their viability. Overall, this work provides evidence of how copper can be combined with azoles to deregulate copper homeostasis, opening new horizons for the development of bifunctional antifungals.


Asunto(s)
Antifúngicos/química , Antifúngicos/farmacología , Candida/efectos de los fármacos , Cobre/química , Ionóforos/química , Triazoles/química , Triazoles/farmacología , Antifúngicos/toxicidad , Supervivencia Celular/efectos de los fármacos , Células HeLa , Humanos , Triazoles/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...